Two Von Willebrand Patients, Two Surgeries: Why the Same Diagnosis Splits Into Two Plans

T.K., a 24-year-old graduate student, has had easy bruising and heavy periods since adolescence, formally diagnosed as Type 1 von Willebrand disease three years ago after a bleeding-history questionnaire finally got taken seriously by a new primary care physician. She is scheduled for extraction of two impacted wisdom teeth next month, a mucosal procedure with a real if modest bleeding risk. At the time of her original diagnosis, a formal desmopressin trial dose was performed specifically to establish whether her disease would respond — not assumed from her subtype alone, since the ASH/ISTH/NHF/WFH guidelines are explicit that Type 1 response is common but not universal — and it showed her factor VIII activity and VWF ristocetin cofactor activity both roughly tripling within an hour, a clear, adequate response.

That test is three years old, and the question in front of the team now is whether a three-year-old response can be trusted to still hold, or whether a repeat trial dose closer to the actual procedure is the more careful move. There is a second, separate wrinkle: her extraction will likely need coverage across more than one day if bleeding occurs postoperatively, and desmopressin loses potency with repeated dosing over 24 to 48 hours as stored endothelial von Willebrand factor is depleted — the tachyphylaxis Mannucci described in the original desmopressin work, and which the 2021 ASH/ISTH/NHF/WFH von Willebrand disease guidelines still name as the reason not to build a multi-day plan on it, that means a plan built only around her single confirmed response may not survive a second or third dose the way an oral surgery recovery sometimes demands.

She has otherwise been a healthy young woman with no other chronic conditions, and the extraction itself is being done specifically because both wisdom teeth are impacted and symptomatic — not an elective cosmetic procedure, but one her oral surgeon has judged necessary regardless of her bleeding disorder, which is part of why the team is planning around it rather than deferring it further.

She swims competitively and has already asked, unprompted, how soon after surgery she can safely return to training — a question the team is treating as a genuine planning input, since a return-to-activity timeline built around her actual bleeding risk, not a generic postoperative default, is part of what makes this a plan she can actually follow.

R.P., a 68-year-old retired postal worker, fell on an icy sidewalk this morning and was found in the emergency department to have a displaced intertrochanteric hip fracture requiring surgical fixation within the next day or two — the kind of injury that does not tolerate the multi-day workup a fully elective procedure could. He carries a Type 2B von Willebrand disease diagnosis, made a decade ago after a postoperative bleeding complication following a knee arthroscopy prompted a specialist workup, and his hematology record from that evaluation carries an explicit, permanent flag: desmopressin is contraindicated for him, not merely unproven.

Type 2B is the variant where the abnormality is qualitative, not just quantitative — his von Willebrand factor binds platelets with an abnormally high affinity even without provocation, and desmopressin, which works by releasing stored von Willebrand factor from endothelial cells, would flood his circulation with more of that same abnormal, over-sticky protein. This is not a theoretical concern the 2021 ASH/ISTH/NHF/WFH guidelines raise in the abstract — they name Type 2B specifically as a subtype where desmopressin is contraindicated rather than merely unproven, precisely because of the thrombocytopenia it can provoke, and his own chart from a prior challenge a decade ago is that exact mechanism playing out in a person rather than a guideline table: a further, acute drop in an already borderline platelet count, the opposite of the correction the drug is meant to provide. His baseline platelet count today is 118,000/µL, at the lower edge of normal, which leaves essentially no room to absorb that kind of drug-induced additional drop before a hip fixation that itself carries meaningful expected blood loss.

He is otherwise a healthy, active 68-year-old with well-controlled hypertension on a single agent and no history of falls before today's ice — the kind of patient whose fixation would ordinarily proceed with routine perioperative planning if not for the specific, mechanism-level conflict his von Willebrand subtype creates with the drug most orthopedic protocols reach for first.

His daughter, a nurse at a different hospital, has already called ahead to make sure the surgical team has his hematology records from a decade ago rather than relying on his own recollection of what happened — a detail the orthopedic team is grateful for, since a documented prior reaction carries more weight in tonight's planning than a secondhand account of one would.